These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 11389994)

  • 21. Hepatic endocytosis of various types of mannose-terminated albumins. What is important, sugar recognition, net charge, or the combination of these features.
    Jansen RW; Molema G; Ching TL; Oosting R; Harms G; Moolenaar F; Hardonk MJ; Meijer DK
    J Biol Chem; 1991 Feb; 266(5):3343-8. PubMed ID: 1993707
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetics of a sustained release formulation of PDGFβ-receptor directed carrier proteins to target the fibrotic liver.
    van Dijk F; Teekamp N; Beljaars L; Post E; Zuidema J; Steendam R; Kim YO; Frijlink HW; Schuppan D; Poelstra K; Hinrichs WLJ; Olinga P
    J Control Release; 2018 Jan; 269():258-265. PubMed ID: 29170138
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reduction of fibrogenesis by selective delivery of a Rho kinase inhibitor to hepatic stellate cells in mice.
    van Beuge MM; Prakash J; Lacombe M; Gosens R; Post E; Reker-Smit C; Beljaars L; Poelstra K
    J Pharmacol Exp Ther; 2011 Jun; 337(3):628-35. PubMed ID: 21383021
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting hepatic stellate cells for cell-specific treatment of liver fibrosis.
    Beljaars L; Meijer DK; Poelstra K
    Front Biosci; 2002 May; 7():e214-22. PubMed ID: 11991830
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Targeting glycyrrhetinic acid to hepatic stellate cells in treating rat liver fibrosis].
    Zhang QS; Luk JM; Zhang J; Tian GY
    Zhonghua Gan Zang Bing Za Zhi; 2005 Sep; 13(9):664-7. PubMed ID: 16174454
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Increased liver uptake and reduced hepatic stellate cell activation with a cell-specific conjugate of the Rho-kinase inhibitor Y27632.
    van Beuge MM; Prakash J; Lacombe M; Post E; Reker-Smit C; Beljaars L; Poelstra K
    Pharm Res; 2011 Aug; 28(8):2045-54. PubMed ID: 21442374
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The pharmacokinetic and biological activity profile of dexamethasone targeted to sinusoidal endothelial and Kupffer cells.
    Melgert BN; Weert B; Schellekens H; Meijer DK; Poelstra K
    J Drug Target; 2003 Jan; 11(1):1-10. PubMed ID: 12852435
    [TBL] [Abstract][Full Text] [Related]  

  • 28. FXR agonist obeticholic acid reduces hepatic inflammation and fibrosis in a rat model of toxic cirrhosis.
    Verbeke L; Mannaerts I; Schierwagen R; Govaere O; Klein S; Vander Elst I; Windmolders P; Farre R; Wenes M; Mazzone M; Nevens F; van Grunsven LA; Trebicka J; Laleman W
    Sci Rep; 2016 Sep; 6():33453. PubMed ID: 27634375
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Expression and matrix deposition of latent transforming growth factor beta binding proteins in normal and fibrotic rat liver and transdifferentiating hepatic stellate cells in culture.
    Breitkopf K; Lahme B; Tag CG; Gressner AM
    Hepatology; 2001 Feb; 33(2):387-96. PubMed ID: 11172340
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The antiproliferative drug doxorubicin inhibits liver fibrosis in bile duct-ligated rats and can be selectively delivered to hepatic stellate cells in vivo.
    Greupink R; Bakker HI; Bouma W; Reker-Smit C; Meijer DK; Beljaars L; Poelstra K
    J Pharmacol Exp Ther; 2006 May; 317(2):514-21. PubMed ID: 16439617
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Homing of negatively charged albumins to the lymphatic system: general implications for drug targeting to peripheral tissues and viral reservoirs.
    Swart PJ; Beljaars L; Kuipers ME; Smit C; Nieuwenhuis P; Meijer DK
    Biochem Pharmacol; 1999 Nov; 58(9):1425-35. PubMed ID: 10513986
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reduction of advanced liver fibrosis by short-term targeted delivery of an angiotensin receptor blocker to hepatic stellate cells in rats.
    Moreno M; Gonzalo T; Kok RJ; Sancho-Bru P; van Beuge M; Swart J; Prakash J; Temming K; Fondevila C; Beljaars L; Lacombe M; van der Hoeven P; Arroyo V; Poelstra K; Brenner DA; Ginès P; Bataller R
    Hepatology; 2010 Mar; 51(3):942-52. PubMed ID: 20044807
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hepatic and intrahepatic targeting of an anti-inflammatory agent with human serum albumin and neoglycoproteins as carrier molecules.
    Franssen EJ; Jansen RW; Vaalburg M; Meijer DK
    Biochem Pharmacol; 1993 Mar; 45(6):1215-26. PubMed ID: 8466542
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An angiotensin II type 1 receptor antagonist, olmesartan medoxomil, improves experimental liver fibrosis by suppression of proliferation and collagen synthesis in activated hepatic stellate cells.
    Kurikawa N; Suga M; Kuroda S; Yamada K; Ishikawa H
    Br J Pharmacol; 2003 Jul; 139(6):1085-94. PubMed ID: 12871826
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Local inhibition of liver fibrosis by specific delivery of a platelet-derived growth factor kinase inhibitor to hepatic stellate cells.
    Gonzalo T; Beljaars L; van de Bovenkamp M; Temming K; van Loenen AM; Reker-Smit C; Meijer DK; Lacombe M; Opdam F; Kéri G; Orfi L; Poelstra K; Kok RJ
    J Pharmacol Exp Ther; 2007 Jun; 321(3):856-65. PubMed ID: 17369283
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prevention of hepatic stellate cell activation using JQ1- and atorvastatin-loaded chitosan nanoparticles as a promising approach in therapy of liver fibrosis.
    Hassan R; Tammam SN; Safy SE; Abdel-Halim M; Asimakopoulou A; Weiskirchen R; Mansour S
    Eur J Pharm Biopharm; 2019 Jan; 134():96-106. PubMed ID: 30471341
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Upregulation of fibronectin but not of entactin, collagen IV and smooth muscle actin by anaphylatoxin C5a in rat hepatic stellate cells.
    Schlaf G; Schmitz M; Heine I; Demberg T; Schieferdecker HL; Götze O
    Histol Histopathol; 2004 Oct; 19(4):1165-74. PubMed ID: 15375759
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hepatic stellate cell-targeted imatinib nanomedicine versus conventional imatinib: A novel strategy with potent efficacy in experimental liver fibrosis.
    El-Mezayen NS; El-Hadidy WF; El-Refaie WM; Shalaby TI; Khattab MM; El-Khatib AS
    J Control Release; 2017 Nov; 266():226-237. PubMed ID: 28965860
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Indole-3-carbinol enhances the resolution of rat liver fibrosis and stimulates hepatic stellate cell apoptosis by blocking the inhibitor of κB kinase α/inhibitor of κB-α/nuclear factor-κB pathway.
    Ping J; Gao AM; Qin HQ; Wei XN; Bai J; Liu L; Li XH; Li RW; Ao Y; Wang H
    J Pharmacol Exp Ther; 2011 Nov; 339(2):694-703. PubMed ID: 21862660
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Studies on the targeted delivery of the antifibrogenic compound mycophenolic acid to the hepatic stellate cell.
    Greupink R; Bakker HI; Reker-Smit C; van Loenen-Weemaes AM; Kok RJ; Meijer DK; Beljaars L; Poelstra K
    J Hepatol; 2005 Nov; 43(5):884-92. PubMed ID: 16083988
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.